Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  Vernalis plc    VER   GB00B3Y5L754

Delayed Quote. Delayed  - 09/27 05:35:05 pm
45 GBp   +2.27%
09/26VERNALIS PLC : annual earnings release
09/13 VERNALIS : Notice of Full Year Results
09/07 VERNALIS : FDA accepts CCP-07 NDA for full review
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
09/21/2016 09/22/2016 09/23/2016 09/26/2016 09/27/2016 Date
44.25(c) 44.5(c) 44(c) 44(c) 45 Last
32 818 7 464 44 549 141 897 148 190 Volume
0.00% +0.56% -1.12% 0.00% +2.27% Change
More quotes
Financials ( GBP)
Sales 2016 11,6 M
EBIT 2016 -30,0 M
Net income 2016 -22,9 M
Finance 2016 46,0 M
Yield 2016 -
Sales 2017 19,8 M
EBIT 2017 -24,9 M
Net income 2017 -24,2 M
Finance 2017 23,9 M
Yield 2017 -
P/E ratio 2016 -
P/E ratio 2017
EV / Sales2016 15,9x
EV / Sales2017 10,5x
Capitalization 232 M
More Financials
Company
Vernalis Plc engages in the research, development, and commercialization of pharmaceutical products under the Tuzistra XR brand.The company was founded by Keith G. McCullagh in 1986 and is headquartered in Winnersh, United Kingdom. 
Sector
Biotechnology & Medical Research
Calendar
09/29 | 08:00amEarnings Release
More about the company
Surperformance© ratings of Vernalis plc
Trading Rating : Investor Rating :
More Ratings
Latest news on VERNALIS PLC
09/26VERNALIS PLC : annual earnings release
09/13 VERNALIS : Notice of Full Year Results
09/07 VERNALIS : FDA accepts CCP-07 NDA for full review
09/06 VERNALIS : Says New Drug Application For CCP-07 Accepted In US
07/19 VERNALIS : Reaches Milestone In French Oncology Collaboration
07/19 VERNALIS : Achieves a Milestone in Its Oncology Collaboration With Servier
07/18 JUNO THERAPEUTICS : Vernalis Notes the Acquisition of RedoxTherapies by Juno The..
07/15 VERNALIS : Notes Juno Therapeutics To Buy Partner RedoxTherapies
07/15 VERNALIS : Notes the Acquisition of RedoxTherapies by Juno Therapeutics
07/11 VERNALIS : Announces Successful Completion of CCP-08 Pivotal Multiple-Dose Compa..
More news
Sector news : Biotechnology & Medical Research - NEC
02:18pDJAMGEN : Myeloma Treatment Study Fails to Meet Primary Endpoint
09/26DJPfizer Throws Out Plan to Split Into Two Companies
09/26DJSANOFI : FDA Accepts Sanofi's, Regeneron's Dermatitis Treatment for Priority Rev..
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- 2nd Update
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- Update
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
03/17 Vernalis ADR reports 6M'15 results
2015 Vernalis acquires U.S. rights to extended-release antibiotic
Advertisement
Chart VERNALIS PLC
Duration : Period :
Vernalis plc Technical Analysis Chart | VER | GB00B3Y5L754 | 4-Traders
Full-screen chart
Technical analysis trends VERNALIS PLC
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Average target price 0,85  GBP
Spread / Average Target 92%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Ian Garland Chief Executive Officer & Executive Director
Peter John Fellner Non-Executive Chairman
David MacKney Chief Financial Officer & Executive Director
Pascal Borderies Senior Vice President-Medical Affairs
Carol C. Ferguson Senior Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
VERNALIS PLC-37.92%300
INCYTE CORPORATION-18.16%16 687
CELLTRION, INC.--.--%11 639
LONZA GROUP AG13.18%9 948
QUINTILES TRANSNATIONA..15.03%9 402
SEATTLE GENETICS, INC.24.13%7 828
More Results